当前位置: X-MOL 学术J. Am. Soc. Nephrol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients
Journal of the American Society of Nephrology ( IF 10.3 ) Pub Date : 2021-12-01 , DOI: 10.1681/asn.2021050689
Baptiste Lamarthée 1 , Carole Burger 1 , Charlotte Leclaire 1 , Emilie Lebraud 1 , Aniela Zablocki 1 , Lise Morin 1 , Xavier Lebreton 2 , Béatrice Charreau 3 , Renaud Snanoudj 4 , Soëli Charbonnier 5 , Tifanie Blein 5 , Mélanie Hardy 6 , Julien Zuber 2, 5 , Simon Satchell 7 , Morgan Gallazzini 1 , Fabiola Terzi 1 , Christophe Legendre 2 , Jean Luc Taupin 6 , Marion Rabant 1, 8 , Claire Tinel 1 , Dany Anglicheau 2, 9
Affiliation  

Background

After kidney transplantation, donor-specific antibodies against human leukocyte antigen donor-specific antibodies (HLA-DSAs) drive antibody-mediated rejection (ABMR) and are associated with poor transplant outcomes. However, ABMR histology (ABMRh) is increasingly reported in kidney transplant recipients (KTRs) without HLA-DSAs, highlighting the emerging role of non-HLA antibodies (Abs).

Methods

W e designed a non-HLA Ab detection immunoassay (NHADIA) using HLA class I and II–deficient glomerular endothelial cells (CiGEnCHLA) that had been previously generated through CRISPR/Cas9-induced B2M and CIITA gene disruption. Flow cytometry assessed the reactivity to non-HLA antigens of pretransplantation serum samples from 389 consecutive KTRs. The intensity of the signal observed with the NHADIA was associated with post-transplant graft histology assessed in 951 adequate biopsy specimens.

Results

W e sequentially applied CRISPR/Cas9 to delete the B2M and CIITA genes to obtain a CiGEnCHLA clone. CiGEnCHLA cells remained indistinguishable from the parental cell line, CiGEnC, in terms of morphology and phenotype. Previous transplantation was the main determinant of the pretransplantation NHADIA result (P<0.001). Stratification of 3-month allograft biopsy specimens (n=298) according to pretransplantation NHADIA tertiles demonstrated that higher levels of non-HLA Abs positively correlated with increased glomerulitis (P=0.002), microvascular inflammation (P=0.003), and ABMRh (P=0.03). A pretransplantation NHADIA threshold of 1.87 strongly discriminated the KTRs with the highest risk of ABMRh (P=0.005, log-rank test). A multivariate Cox model confirmed that NHADIA status and HLA-DSAs were independent, yet synergistic, predictors of ABMRh.

Conclusion

The NHADIA identifies non-HLA Abs and strongly predicts graft endothelial injury independent of HLA-DSAs.



中文翻译:

CRISPR/Cas9 工程化的 HLA 缺失肾小球内皮细胞作为预测肾移植受者致病性非 HLA 抗体的工具

背景

肾移植后,针对人类白细胞抗原供体特异性抗体 (HLA-DSAs) 的供体特异性抗体会引发抗体介导的排斥反应 (ABMR),并与移植结果不佳相关。然而,ABMR 组织学 (ABMRh) 在没有 HLA-DSA 的肾移植受者 (KTR) 中的报道越来越多,突出了非 HLA 抗体 (Abs) 的新兴作用。

方法

我们使用 HLA I 类和 II 类缺陷型肾小球内皮细胞 (CiGEnC) 设计了一种非 HLA 抗体检测免疫测定 (NHADIA)HLA),之前是通过 CRISPR/Cas9 诱导的B2MCIITA基因破坏产生的。流式细胞术评估了来自 389 个连续 KTR 的移植前血清样本对非 HLA 抗原的反应性。用 NHADIA 观察到的信号强度与在 951 个足够的活检标本中评估的移植后移植物组织学相关。

结果

我们依次应用 CRISPR/Cas9 删除B2MCIITA基因以获得 CiGEnCHLA克隆。CiGEnCHLA 细胞在形态和表型方面与亲代细胞系 CiGEnC 无法区分。既往移植是移植前 NHADIA 结果的主要决定因素 ( P <0.001)。根据移植前 NHADIA 三分位数对 3 个月同种异体移植活检标本 ( n = 298) 进行分层表明,较高水平的非 HLA 抗体与肾小球炎 ( P = 0.002)、微血管炎症 ( P = 0.003) 和 ABMRh ( P =0.03)。1.87 的移植前 NHADIA 阈值强烈区分了具有最高 ABMRh 风险的 KTR(P=0.005,对数秩检验)。多变量 Cox 模型证实 NHADIA 状态和 HLA-DSA 是 ABMRh 的独立但协同的预测因子。

结论

NHADIA 识别非 HLA 抗体,并强烈预测独立于 HLA-DSA 的移植物内皮损伤。

更新日期:2021-11-30
down
wechat
bug